Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis

INTRODUCTION: Maximizing responses of malignant gliomas is hampered by resistance to temozolomide (TMZ). Increasing efficacy but not toxicity is a key issue when testing drug combinations. The antimyeloma agent bortezomib (BZ) has shown promising results in vitro and is currently being tested in gli...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlachostergios, Panagiotis J., Papandreou, Christos N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2013
Materias:
Basic Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424237/
https://www.ncbi.nlm.nih.gov/pubmed/25995745
http://dx.doi.org/10.5114/aoms.2013.36919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424237/
https://www.ncbi.nlm.nih.gov/pubmed/25995745
http://dx.doi.org/10.5114/aoms.2013.36919

Ejemplares similares